Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Tohoku Univ, JPMA, MICIN Launch Pilot Study on Wearable Data Collection
Tohoku University’s Tohoku Medical Megabank Organization (ToMMo), the Japan Pharmaceutical Manufacturers Association (JPMA), and medical data solution provider MICIN have started a pilot study aimed at the application of wearable devices in collecting objective data on people’s lifestyles, such as…
To read the full story
Related Article
- Tohoku Univ., Drug Makers, MICIN to Jointly Collect Lifestyle Data with Wearable
May 24, 2022
- Takeda, Tohoku University Ink Joint Research Pact on Whole Genome Sequencing
April 20, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
- JPMA, Tohoku Medical Megabank to Start Collaborative Research on Preemptive Health
January 30, 2020
- Pharma Companies Mull Use of Tohoku University’s Database for Drug Discovery: JPMA Official
December 18, 2018
ORGANIZATION
- Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
- FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
- AMDD to Continue Policy Advocacy to Address Device Lag and Loss: Chair
January 28, 2026
- Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says
January 23, 2026
- Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…